compname reports qtrly earnings per share of $0.54.
qtrly earnings per share $0.54.
continued confidence in sales outlook; fy 2021 adjusted earnings per share guidance of $2.07 to $2.27 increased $0.07.
sees q2 2021 total sales to be between $1.25 and $1.33 billion & adjusted earnings per share of $0.54 to $0.60.
qtrly sales grew 8% to $1.2 billion; underlying sales grew 5%.
overall, full year 2021 sales guidance remains at $4.9 to $5.3 billion.
qtrly global transcatheter aortic valve replacement sales of $792 million, up 7% on reported basis.
remains confident that tavr global opportunity will exceed $7 billion by 2024.
continues to anticipate underlying tavr sales growth in 15 to 20 percent range in 2021.
